Core Viewpoint - The company reported a year-on-year decline in total revenue of approximately 6.9% to about HKD 323 million for the six months ending September 30, 2025, primarily due to weakened sales performance in traditional Chinese medicine, Western medicine, and health food products [1] Financial Performance - The company recorded a profit attributable to shareholders of approximately HKD 2.8 million, a significant decrease from approximately HKD 23.7 million for the same period ending September 30, 2024 [1] - Earnings per share were reported at HKD 0.025 [1] Market and Sales Dynamics - The decline in revenue was attributed to weak consumer sentiment in the retail market, leading to a reduction in gross profit and a significant drop in net gains from property sales, as well as a decrease in fair value gains from investment properties [1] Product Innovation and Marketing - The company continues to commit to product innovation, successfully launching a marketing campaign combining outdoor and digital promotions for its popular health product, which has seen significant sales growth [1] - New marketing campaigns are planned for flagship products such as An Gong Niu Huang Wan and Hou Zao Chu Tan San for the upcoming autumn and winter seasons [1] Regulatory Developments - The company has been closely collaborating with relevant Chinese authorities following the announcement of simplified approval processes for traditional Chinese medicine in the Greater Bay Area [1] - The company announced that Hou Zao Chu Tan San has been approved as the first OTC product in Hong Kong under this new process, which will allow millions of consumers in mainland China to access the product conveniently starting next year [1]

Core Viewpoint - The approval of the "Monkey Zao Chutian San" by the National Medical Products Administration marks a significant milestone for the company, indicating the successful implementation of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bitian Tang (00897), rose by 11.36% to HKD 0.49, with a trading volume of HKD 2.5302 million [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey Zao Chutian San," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval represents the first product to be granted market access under the newly simplified registration policy for traditional Chinese medicine, highlighting the effectiveness of regulatory changes in the industry [1]

Core Viewpoint - The approval of the "Monkey's Paw Phlegm-Removing Powder" for mainland market entry marks a significant milestone for the company, reflecting the effectiveness of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bit Yuan Tang (00897), rose over 11%, reaching a price of 0.49 HKD with a trading volume of 2.53 million HKD [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey's Paw Phlegm-Removing Powder," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval of the product is the first instance of a traditional Chinese medicine being granted entry into the mainland market under the new simplified registration policy, indicating a positive trend for the industry [1]